comprehensive -WSS

comprehensive

author：leisure time 2025-09-06 04:28:39 - browse：773

Balance innovation — Medicare laid out in the greatest detail yet how it will choose which drug prices it will negotiate in its brand-new program, and how it will figure out what the government’s opening offer will be. Adobe

WASHINGTON — Medicare laid out Wednesday in the greatest detail yet how it will choose which drug prices it will negotiate in its brand-new program, and how it will figure out what the government’s opening offer will be.

Democrats outlined some parts of the process in the Inflation Reduction Act that passed Congress last August, but the details of how drugs will be selected and what factors will be considered have been vague until now. Though the actual negotiated prices won’t take effect for years, Medicare officials must announce the first 10 drugs they’ll negotiate over by Sept. 1.

The guidance clarifies that the agency will choose the 50 pharmacy drugs that cost Medicare the most money, based on gross expenditures. If drugs have the same cost to the program, then the one that has been approved longer will be ranked higher.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： New safety details link Apellis eye drug to rare cases of blindness

WSS

Vertex non

How climate

NIH launches clinical trials and new research office for long Covid

First Opinion Podcast: Long Covid needs a new approach

STAT Summit: How a Chicago ER doctor tackles gun violence

‘Oppenheimer’ and the risks of AI in health care

explore

comprehensive

knowledge

Wildfire smoke exposes gaps in outdoor worker protections

The explosion of genetic testing requires a new approach

The high cost of giving birth even with insurance

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Moonlake's readout produced a cash windfall. Risks remain

Studies point to risks of excluding people with obesity from drug trials

Medical leaders decry Supreme Court decision on affirmative action

Scientists inch closer to single

hotspot

Will Ozempic

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

The EU Joint Clinical Assessment needs to live up to its promise

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

STAT Summit: Michael J. Fox on progress in Parkinson's research

STAT Summit: How a Chicago ER doctor tackles gun violence

hotspot

focus

knowledge

focus